ORIGINALCONTRIBUTION
Annual High-Dose Oral Vitamin D
and Falls and Fractures in Older Women
A Randomized Controlled Trial
KerrieM.Sanders, PhD
Context ImprovingvitaminDstatusmaybeanimportantmodifiableriskfactortore-
AmandaL.Stuart, BappSc ducefallsandfractures;however,adherencetodailysupplementationistypicallypoor.
ElizabethJ.Williamson, MA,PhD Objective Todeterminewhetherasingleannualdoseof500000IUofcholecalcif-
eroladministeredorallytoolderwomeninautumnorwinterwouldimproveadher-
JulieA.Simpson, PhD
enceandreducetheriskoffallsandfracture.
MarkA.Kotowicz, MBBS,FRACP
Design,Setting,andParticipants Adouble-blind,placebo-controlledtrialof2256
DorisYoung, MD,MBBS,FRACGP community-dwellingwomen,aged70yearsorolder,consideredtobeathighriskof
GeoffreyC.Nicholson, PhD,FRACP fracturewererecruitedfromJune2003toJune2005andwererandomlyassignedto
receivecholecalciferolorplaceboeachautumntowinterfor3to5years.Thestudy
T
HE RESULTS OF RANDOMIZED concludedin2008.
controlled trials investigating
Intervention 500000IUofcholecalciferolorplacebo.
the effects of cholecalciferol
MainOutcomeMeasures Fallsandfractureswereascertainedusingmonthlycal-
(vitamin D) supplementation
endars;detailswereconfirmedbytelephoneinterview.Fractureswereradiologically
onfallsandfractureshavebeenincon-
confirmed.Inasubstudy,137randomlyselectedparticipantsunderwentserialblood
sistent.1-13 Some meta-analyses con- samplingfor25-hydroxycholecalciferolandparathyroidhormonelevels.
cludethat700to800IUofvitaminD
Results Womeninthecholecalciferol(vitaminD)grouphad171fracturesvs135in
daily reduces fracture risk by 13% to
theplacebogroup;837womeninthevitaminDgroupfell2892times(rate,83.4per
26%,14-18whereasothersconcludethat
100person-years)while769womenintheplacebogroupfell2512times(rate,72.7
vitamin D is ineffective. A Cochrane per100person-years;incidencerateratio[RR],1.15;95%confidenceinterval[CI],
analysis19 and the Vitamin D Indi- 1.02-1.30; P=.03). The incidence RR for fracture in the vitamin D group was 1.26
vidual Patient Analysis of Random- (95%CI,1.00-1.59;P=.047)vstheplacebogroup(ratesper100person-years,4.9
ized Trials (DIPART) group,20 pub- vitaminDvs3.9placebo).Atemporalpatternwasobservedinaposthocanalysisof
lished after this study commenced, falls.TheincidenceRRoffallinginthevitaminDgroupvstheplacebogroupwas1.31
inthefirst3monthsafterdosingand1.13duringthefollowing9months(testfor
showedanonstatisticallysignificantin-
homogeneity; P=.02). In the substudy, the median baseline serum 25-
crease in hip fracture risk associated
hydroxycholecalciferolwas49nmol/L.Lessthan3%ofthesubstudyparticipantshad
with vitamin D supplementation.19-21
25-hydroxycholecalciferollevelslowerthan25nmol/L.InthevitaminDgroup,25-
Studies have observed those living in hydroxycholecalciferollevelsincreasedat1monthafterdosingtoapproximately120
long-term care facilities as having nmol/L,wereapproximately90nmol/Lat3months,andremainedhigherthanthe
greater fracture risk reduction than placebogroup12monthsafterdosing.
community-dwelling elders. Simi- Conclusion Amongoldercommunity-dwellingwomen,annualoraladministration
larly,fewerfractureswereobservedin ofhigh-dosecholecalciferolresultedinanincreasedriskoffallsandfractures.
participantswhosestudytreatmentwas
TrialRegistration anzctr.org.auIdentifier:ACTR12605000658617;isrctn.orgIden-
coadministeredwithcalcium.4,5,16,22Fur-
tifier:ISRCTN83409867
thermore, many studies have found
JAMA.2010;303(18):1815-1822 www.jama.com
treatmentadherencetobelow1,2,6and
fracture risk reduction was greater AuthorAffiliations:DepartmentofClinicalandBiomedi- RoyalChildren’sHospital(DrWilliamson);andDepart-
calSciences,BarwonHealth,UniversityofMelbourne, mentofGeneralPractice,UniversityofMelbourne,Park-
amongadherentthannonadherentpa- Geelong(DrsSanders,Kotowicz,andNicholsonandMs ville,Victoria(DrYoung),Australia.
Stuart);CentreforMolecular,Environmental,Genetic CorrespondingAuthor:KerrieSanders,PhD,Depart-
andAnalyticEpidemiology,SchoolofPopulationHealth, mentofClinicalandBiomedicalSciences,Barwon
Foreditorialcommentseep1861. UniversityofMelbourne,Carlton(DrsWilliamsonand Health,POBox281,Geelong,Victoria,Australia3220
Simpson);MurdochChildren’sResearchInstitute,and (kerrie@barwonhealth.org.au).
©2010AmericanMedicalAssociation.Allrightsreserved. (ReprintedwithCorrections)JAMA,May12,2010—Vol303,No.18 1815
Downloaded From: http://jama.jamanetwork.com/ by a Purdue University User on 05/18/2015
HIGH-DOSEVITAMINDANDFALLSANDFRACTURESINWOMEN
ciferoladministeredintramuscularlyas tomg/dL,divideby88.4;andserumvi-
Figure1.PatientFlowDiagram
asingleannualdose.7Thestudywasde- tamin D from nmol/L to ng/mL, di-
signedsothatthevitaminDtreatment videby2.496.)
7204Women aged >70 years
were invited to participate would prevent decreases in 25- Eligible participants were random-
hydroxycholecalciferol over winter,25 ized to receive either 500000 IU of
4887Excluded
2486Declined addresslowadherence,andbeaprac- cholecalciferol or identical placebo.
invitation tical intervention easily translated to Allocation was performed by an inde-
1579Did not meet
inclusion clinicalpractice. pendent statistician using computer-
criteria
generated randomization of numbers
822Declined
participation METHODS performedinblocksof500.Treatment
StudyDesign allocationstatuswase-maileddirectly
2317Consented to participate
TheVitalDstudywasasingle-center, to the hospital clinical trials pharma-
59Withdrew prior to double-blind, randomized, placebo- cist responsible for dispensing study
randomization
controlled trial involving women 70 medication. The participants and
2258Randomized yearsorolderresidinginsouthernVic- study staff were blinded to interven-
toria,Australia(latitude38°S).Thepar- tiongroup.
1131Randomized to 1127Randomized to
receive 500 000 IU receive placebo ticipantswererecruitedbetween2003 Study medication was supplied by
of cholecalciferol and 2005 and were randomly as- PSMHealthcare,Auckland,NewZea-
signed to receive either a single oral land. Ten tablets were mailed to par-
1131Received treatment 1127Received treatment
as assigned as assigned dose of cholecalciferol 500000 IU or ticipantsannually(March-August,de-
1131Year 1 1127Year 1
1074Year 2 1063Year 2 matched placebo each year for 3 to 5 termined by recruitment date) with
1013Year 3 1008Year 3
years (in autumn or winter). Partici- instructionstotakealltabletsonasingle
217Year 4 222Year 4
45Year 5 50Year 5 pantswerefollowedupfor12months day. Study staff confirmed by tele-
after their last dose of study medica- phonetheingestionofstudymedica-
116Withdrawn 110Withdrawn
40Died 47Died tionin2007. tionwithin2weeks.Subsequentdos-
29Became ill 23Became ill
14Lacked interest 17Lacked interest The study was approved by the in- ing occurred within 2 weeks of the
13Thought they 8Thought they stitutional review boards of Barwon anniversaryofthefirstdose.
were too old were too old
or developed or developed Health and the University of Mel-
dementia dementia
8Left for personal 6Left for personal bourneandcarriedoutincompliance OutcomeMeasures
reasons reasons withtheHelsinkiDeclaration.Allpar- Participants’ age, calcium intake, and
12Other 9Other
ticipants provided written informed fracture-risk profile were collected at
1131Included in the 1125Included in the consent. baselinebyquestionnaire.Fallswerede-
primary analysis primary analysis
2Excluded (incomplete The study recruited 2317 commu- finedas“aneventreportedeitherbythe
fall ascertainment) nity-dwellingwomenaspreviouslyde- faller or a witness, resulting in a per-
scribed.26Invitationlettersweresentto soninadvertentlycomingtorestonthe
allage-eligiblewomenlistedontheelec- groundoranotherlowerlevel,withor
tients.1,16,22TheevidenceofvitaminD toralrolloftheregionsurroundingthe without loss of consciousness or in-
efficacyinpreventingfallssuggeststhat studycenter.Votingiscompulsoryin jury.”28Thisdefinitionwasexplained
dailydosesofatleast700IUreducefalls Australia. to participants and reinforced twice
by19%to26%.23 Womenwereincludedinthestudy yearlyvianewsletter.
Wehypothesizedthathigh-dosecho- iftheywereathigherriskofhipfrac- Allcontactwithparticipantswasby
lecalciferol (500000 IU) given orally ture,27definedbycriteriasuchasma- mail and telephone. Falls and frac-
once a year to community-dwelling ternalhipfracture,pastfracture,orself- tureswererecordedusingpostcardcal-
older women would reduce falls and reportedfaller.26Womenwereexcluded endarscompleteddailybywritingFif
fractures.Therationaleforthisdosewas if they could not provide informed theyhadafall,fracture,orbothandN
based on data that an oral dose of consent or information about falls or if they did not and were returned
500000IU(administeredas50000IU fractures;permanentlyresidedatahigh- monthly by prepaid post.26,29 Partici-
daily for 10 days) produced a mean level care facility; had an albumin- pants unable to send postcards were
(SD)increasein25-hydroxycholecal- correctedcalciumlevelhigherthan2.65 telephonedmonthly.
ciferol of 32 (15) nmol/L at 17 (7) mmol/L;orhadacreatininelevelhigher When a fall or fracture was indi-
weeksafterdose24andwassupported than 150 µmol/L, or currently took cated,astandardizedquestionnairere-
by fracture-reduction benefits using vitaminDdosesof400IUormore,cal- cording details was administered by
300000ofIUcholecalciferol(admin- citriol,orantifracturetherapy.(Tocon- telephone. Only fractures radiologi-
isteredas100000IUevery4months)3 vert calcium from mmol/L to mg/dL, cally confirmed were included in the
and150000to300000IUofergocal- divideby0.25;creatininefromµmol/L analyses. Seventy-three self-reports
1816 JAMA,May12,2010—Vol303,No.18(ReprintedwithCorrections) ©2010AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a Purdue University User on 05/18/2015
HIGH-DOSEVITAMINDANDFALLSANDFRACTURESINWOMEN
wereunconfirmedbecauseof1ofthe
Table1.BaselineCharacteristicsofParticipantsa
followingreasons:(1)notx-rayed(eg,
VitaminD(n=1131) Placebo(n=1125)
suspected rib fracture), 13 vitamin D
Age,median(IQR),y 76.0(73.1-80.2)b 76.1(73.0-79.7)b
vs15placebo;(2)radiologist’sreport
Baselineriskprofilereportedbyparticipant
statednofracture,19vitaminDvs23
Self-orphysician-reportedhighriskoffalling 449(39.7) 429(38.1)
placebo; and (3) vertebral deformity Brokenbonesinceage50yb 384(36.5) 343(32.7)
withlessthan20%heightreduction,2 Motherhadbrokenhipc 98(10.0) 99(10.1)
vitaminDvs1placebo.Fallswereclas- Everusedwalkingaid 294(26.0) 275(24.4)
sifiedas“resultingfromactivebehav- Baselinecalciumintake,mgd
ior”’whentheparticipant,atthetime (cid:3)800 382(34) 352(32)
of the fall, was walking, gardening, 800-1100 318(28) 283(25)
shopping, doing housework, engag- 1101-1300 135(12) 168(15)
inginsports,rushing,orclimbingalad- (cid:4)1300 273(24) 296(26)
derorchair.Othercircumstancessur-
Biochemicalmeasures,median(IQR)e
25-hydroxycholecalciferol,nmol/L 53(40-65) 45(40-57)
rounding falls were classified as
PTH,pmol/L 4.3(2.9-7.0) 5.0(3.7-6.6)
nonactivebehavior.Calciumintakewas
Abbreviations:IQR,interquartilerange,PTH,parathyroidhormone.
quantifiedannuallybyquestionnaire.30 SIconversionfactors:Toconvert25-hydroxycholecalciferolfromnmol/Ltong/mL,divideby2.496;PTHfrompmol/L
topg/mL,divideby0.1053.
The150substudyparticipantswere aResultsareexpressedasNo.(%)ofparticipantsinthegroupsunlessotherwisespecified.
randomlyselectedandresultswereas- bTotalnumberofparticipantswhocompletedthequestionwere1053inthevitaminDgroupand1050intheplacebo
group.
sayed in a manner blinded to treat- cTotalnumberofparticipantswhocompletedthequestionwere985inthevitaminDgroupand985intheplacebo
mentgroup.Serum25-hydroxychole- dBg ar so eu lp in.
ecalciumquestionnairenotcompletedby49participants:23inthevitaminDgroupand26intheplacebo
calciferol (DiaSorin, Stillwater, group.
eBiochemicalmeasureswereperformedonasubsetof131participants:74inthevitaminDgroupand57inthepla-
Minnesota)andintactparathyroidhor- cebogroup.
mone ([PTH]; Advia Centaur Si-
emens, Deerfield, Illinois) was mea-
suredatbaselineand12monthsafter measures between treatment groups ticipant’sfallsandfracturesatthedif-
dose. In 2006 and 2007, measure- wereperformedusing(cid:2)2testsorWil- ferent time periods. Estimated inci-
ments were also performed 1 and 3 coxonrank-sumtests,asappropriate. dence rate ratios (RRs) for 0 through
monthsafterdose. Theprimaryoutcomemeasures,num- 3monthsand4through12monthsaf-
bers of falls and fractures, were ana- terdosingarepresentedwiththePvalue
SampleSize lyzed using Poisson regression mod- testingforhomogeneityofthe2inci-
Based on 80% power and 5% level of elswithrobuststandarderrorstoallow denceRRs.
significance, we calculated that 6855 fornonindependenceofmultipleevents No adjustment was made for mul-
person-years were needed to detect a forthesameparticipant.Themodelsin- tipletesting.AllPvaluesare2-sidedto
22%relativedifferenceinfracturerates.7 cludedonlytreatmentgroupbutwere detect differences, P(cid:3).05. Analyses
Ourpreviousworkdemonstratesa3.3% also fitted adjusting for baseline cal- were performed in Stata 10.1 (Stata-
fracturerateamongwomenolderthan ciumintake((cid:3)800mg,800-1100mg, Corp,CollegeStation,Texas).
70 years31 and suggests that hip and 1100-1300mg,or(cid:4)1300mg)andage. Althoughadverseeventsweremoni-
forearmfracturescouldbereducedby Thedatawerealsoanalyzedusingnega- tored,therewasnotadataandsafety
16%and31%,respectively,ifsummer- tivebinomialregressionmodelsthatex- monitoringboardorstoppingrulesbe-
time fracture rates were maintained plicitly allow for overdispersion. For cause at the time the study com-
throughouttheyear.32Byusinginclu- comparisonwithsimilarstudies,time menced,thesewerenotusualpractice
sioncriteriabasedonriskfactorsforhip to first fracture and fall was analyzed for vitamin D randomized controlled
fracture, we estimated that our study usingCoxproportionalhazardsmod- trials.USFoodandDrugAdministra-
participantswouldhaveafracturerate els.Kaplan-Meierplotsofcumulative tionandEuropeanMedicinesAgency
3-fold higher than community- incidencearepresented. guidelinesdidnotindicateaneed,and
dwellingwomenofthesameage. Posthocanalyseswereundertaken basedonpublisheddata,wehadnoex-
to investigate the relationship be- pectationofharm.
StatisticalMethods tween the treatment effect and time
RESULTS
Allanalyseswereintention-to-treat.Fall sinceingestingtheannualdose.Each
andfracturedatawereinclusivefrom yearoffollow-upwassplitinto2fol- Enrollmentandoutcomesareshownin
dateoffirststudymedicationtoeither low-up segments: at 3 months and 9 FIGURE1.Therewasnodifferencebe-
completionorthelastcompletemonth monthsafterdosing.Ageneralizedes- tweenthetreatmentgroupsinthepro-
of data (withdrawn or lost to follow- timatingequationapproachwasused portion who withdrew nor in the
up). Initial comparisons of outcome toallowforcorrelationbetweenapar- reasonsforwithdrawal.Allotherpar-
©2010AmericanMedicalAssociation.Allrightsreserved. (ReprintedwithCorrections)JAMA,May12,2010—Vol303,No.18 1817
Downloaded From: http://jama.jamanetwork.com/ by a Purdue University User on 05/18/2015
HIGH-DOSEVITAMINDANDFALLSANDFRACTURESINWOMEN
ticipantswerefollowedupuntilthepre- On 163 occasions, participants did other participants. At the end of the
determinedstudyendin2008.Thepro- notreceiveadoseofstudymedication study, approximately 6% in the pla-
portionwhocommencedantifracture but continued to participate in the cebo group (as of 2008, 65 of 1125)
therapy during the intervention pe- studyandwereincludedintheanaly- and3%(38of1131)inthevitaminD
riod did not differ (90 of 1131 in the sis. On 105 of these occasions, doses group were taking more than 400
vitaminDvs87of1125intheplacebo wereheldbecause44inthevitaminD IU/dofvitaminDsupplements.
group;P=.84). and 61 in the placebo group reported
The groups did not differ signifi- takingmorethan400IUofvitaminD FallOutcomes
cantlybyage,riskprofile,calciumin- supplementation.On58occasions,33 The 2256 participants had a total of
take,orbiochemistry(TABLE1).Thepro- in the vitamin D and 25 in the pla- 5404fallsover6925person-years.Sev-
portionwhoreceivedmedicationineach cebo group declined a dose of study enty-fourpercentof1131womeninthe
month(March-August)wasevenlydis- medication. Ingestion of study medi- vitamin D group and 68% of 1125
tributedbetweenthegroups(P=.66). cation was confirmed annually for all womenintheplacebogrouphadatleast
1fall(TABLE2).ThevitaminDgroup
had2892fallsatarateof83.4per100
Table2.SummaryofFallsandFracturesa person-years vs 2512 in the placebo
Follow-up VitaminD(n=1131) Placebo(n=1125) P Valueb groupatarateof72.7per100person-
Intervention,median(IQR),y 2.96(2.92-3.00) 2.96(2.92-3.00) .60 years (incidence RR, 1.15; (95% CI,
Totalinterventiontime,y 3467.8 3457.4 1.02-1.30; P=.03; TABLE 3). The re-
TotalNo.offallsandfracturesc 2926 2538 sultsdidnotchangeafteradjustingfor
Falls,No.(%) agenorwhenanalyzedusingnegative
0 294(26.0) 356(31.6)
binomialregressiontoallowforoverdis-
1 279(24.7) 246(21.9) .01
persion. The cumulative incidence of
(cid:5)2 558(49.3) 523(46.5)
first fall was increased in the vitamin
(cid:5)4 258(22.8) 235(20.9)
Dgroup(hazardratio[HR],1.16;95%
(cid:5)8 72(6.4) 55(4.9)
CI,1.05-1.28;P=.003;FIGURE2).
(cid:5)1fall 837(74.0) 769(68.4) .003
Increased falls in the vitamin D
Fallsandoutcomes,No.
Totalfallsd 2892 2512 group were observed for each classi-
Withfractured 137 109 fication of falls: falls with fracture,
Withoutfractured 2755 2403 falls without fracture, and falls with
Withsofttissueinjuryd,e 1710 1488 .02e soft tissue injury (Table 2). The pro-
portionoffallsthatresultedinaphy-
Fractures,No.
Totalfracturesd 171 135 sicianvisitdidnotdiffer:27.2%(778
Withoutfalld 34 26 of 2892) in the vitamin D group vs
(cid:5)1Nonvertebralfracturef 124 101 26.1% (657 of 2512) in the placebo
aResultsareexpressedasnumber(%)ofparticipantsinthegroupsunlessotherwisespecified. group.
b(cid:2)2Testsforbinaryoutcomes,Wilcoxonrank-sumtestsforcontinuousoutcomes.
cFallsresultinginafracturearecountedasoneevent.
dCountingeachevent;onepersoncancontributemorethanonce. FractureOutcomes
eReferstobruise,abrasion,ormuscleinjurywithoutfracture;Pvaluereferstoincidencerateratio(1.15,95%confi-
denceinterval,1.02-1.29). Onehundredfifty-fivewomenreceiv-
fThenumberofparticipantswithatleast1nonvertebralfracture.Thenumberofparticipantswithatleast1fractureat
ingvitaminDsustained171fractures
thefollowingsiteswere(vitaminD,placebogroups,respectively)hip(19,15),colles(26,23),otherforearm(14,7),
vertebral(35,28),humerus(15,14),ribs(6,7),clavicle/scapula(4,1),pelvis(8,4),upperleg/patella(8,6),lowerleg and 125 receiving placebo sustained
(6,5),ankle(8,12),foot/toes(17,12),hand/fingers(6,3),andskull/facialbones(8,4).
135 fractures (Table 2). The fracture
rateinthevitaminDgroupwas4.9per
100person-yearsvs3.9intheplacebo
Table3.IncidenceRateRatioforFallsandFracturesandAnalysisAdjustedby
CalciumIntake group. The incidence RR for fracture
IncidenceRateRatioforVitaminDGroup, was1.26(95%CI,1.00-1.59;P=.047)
Estimate(95%ConfidenceInterval) P Value comparedwiththeplacebogroup.Simi-
Noadjustment,No. larly,thenonvertebralfractureRRwas
Falls 1.15(1.02-1.30) .03
1.28 in the vitamin D group (inci-
Fractures 1.26(1.00-1.59) .047
dence RR, 1.28; 95% CI, 1.00-1.65;
Nonvertebralfractures 1.28(1.00-1.65) .06
P=.06).TheHRcumulativeincidence
Adjustedforcalcium
intake,No. of first fracture was 1.26 in the vita-
Fallsadjusted 1.16(1.03-1.31) .02 min D group compared with the pla-
Fracturesadjusted 1.25(0.99-1.58) .06 cebogroup(95%CI,0.99-1.59;P=.06;
Nonvertebralfractures 1.27(0.98-1.65) .08 Figure2).
1818 JAMA,May12,2010—Vol303,No.18(ReprintedwithCorrections) ©2010AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a Purdue University User on 05/18/2015
Thefrequencyoffallsamongwomen groupand58fromtheplacebogroup. (ie, just prior to the second through
whosustainedafracturedidnotdiffer Onesamplefromeachgroupwasex- fifth annual dose administrations and
between groups with a median of 2 cluded because 25-hydroxycholecal- at study completion). There was a
falls (interquartile range [IQR], 1-4) ciferol levels of 123 nmol/L and 115 marked increase in 25-hydroxy-
throughoutthestudycourse. nmol/Lsuggestedthatthewomenwere cholecalciferol levels in the vitamin D
taking more than 400 IU vitamin D group with some evidence of this
TemporalEffectofAnnualDose supplementationperday. increasetrailingofftowardtheendof
TheincidenceRRoffallsinthevitamin Atbaseline,themedian25-hydroxy- the trial. The median 25-hydroxy-
Dgroupwas1.31inthefirst3months cholecalciferol level was 49 nmol/L cholecalciferol levels 12 months after
(95%CI,1.12-1.54)followingdosing, (IQR,40-63;normallowerlimit,(cid:4)50 dose in the vitamin D group ranged
butonly1.13(95%CI,0.99-1.29)dur- nmol/L). Less than 3% of the sub- from55nmol/Lto74nmol/Loverthe
ingtheremaining9monthsoftheyear studyparticipantshad25-hydroxycho- 5 intervals with individual values
(Pvalueforhomogeneity=.02;TABLE4). lecalciferollevelslowerthan25nmol/L. ranging from 25 nmol/L to 120
Thetemporalpatternofexcessfallswas The 25-hydroxycholecalciferol and nmol/L(FIGURE3). The medians and
observedeachyearexceptthefirstyear. PTHlevelsdidnotdifferbetweenthe IQRs of the PTH levels remained
Although not statistically signifi- groups(Table1).Approximatelyhalf stable12monthsafterdosing.
cant,thetemporalpatternobservedin of the substudy participants had 25- In2006and2007,sampleswerecol-
falls was also observed in fractures hydroxycholecalciferol levels of 50 lectedat1and3monthsafterdosein
(Table 3). The vitamin D fracture in- nmol/Lorlower(vitaminD,45.9%vs 102 (74%) of the substudy partici-
cidence RR compared with the pla- 61.4%,placebo)butlessthan5%had pants. The median 25-hydroxychole-
cebo group was 1.53 (95% CI, 0.95- levelsof25nmol/Lorlower(vitamin calciferollevelinthevitaminDgroup
2.46)inthefirst3monthsafterdosing D,4.0%vs3.5%,placebo). 1 month after dose was slightly
and1.18(95%CI,0.91-1.54)duringthe In each year of the study, samples more than 120 nmol/L with 82% at
following9months. were obtained 12 months after dose 100 nmol/L or higher and 24% at
CalciumIntake
andQuestionnaireData Figure2.Kaplan-MeierPlotsofCumulativeIncidenceofTimetoFirstFractureandFirstFall
Theproportionofparticipantswithcal-
Falls Fractures
ciumintakeoflessthan800mg/dde- 100
HR, 1.16 (95% CI, 1.05-1.28) HR, 1.26 (95% CI, 0.99-1.59) creased from 33% at baseline to 27%
P = .003 P = .06
over the subsequent annual assess- 75
ments, whereas the proportion con- Vitamin D
Placebo
suming 1100 mg or more increased 50
Vitamin D
from40%to46%.Therewasnodiffer-
25 Placebo
encebetweenthegroupsinthecatego-
ries of calcium intake (Table 1). The
median daily calcium intake was 976 0 1 2 3 4 1 2 3 4
Trial Year Trial Year
mg(IQR,691-1311mg).
No. of women
Theincreasedriskofbothfallsandfrac- Vitamin D1131 588 382 77 22 1131 1048 963 236 106
Placebo 1125 635 429 87 33 1125 1050 985 253 115
tures in the vitamin D group did not
changeafteradjustingforbaselinecalcium
intake. The overall calcium-adjusted
incidenceRRoffallingwas1.16(95%CI,
1.03-1-31);forfracture,1.25(95%CI,
0.99-1-58; Table 3) in the vitamin D
group.Thegroupshadasimilarpropor-
tionoffallsoccurringduringactivebe-
havior(79%vs81%,respectively).
BiochemistrySubstudy
Ninety-one percent (137 of 150) of
thoseinvitedtoparticipateinthebio-
chemistry substudy consented. Base-
line samples were collected from 133
participants, 75 from the vitamin D
%
,sllaF
fo
ecnedicnI
evitalumuC
25
20
15
10
5
0
%
,serutcarF
fo
ecnedicnI
evitalumuC
HIGH-DOSEVITAMINDANDFALLSANDFRACTURESINWOMEN
Thisanalysiscensorsdataafterfirstfallorfracture.TimetofirstfractureandfallwasanalyzedusingCoxpro-
portionalhazardsmodels.CIindicatesconfidenceintervals;HR,hazardratio.
Table4.TemporalPatternofRiskinFallsandFracture0to3Monthsand4to12Months
AfterTreatment
IncidenceRateRatioforVitaminDGroup,
Estimate(95%ConfidenceInterval)a P Value
Timeaftertreatment,mo
Falls
Within3 1.31(1.12-1.54) .001
After3 1.13(0.99-1.29) .08
Fracture
Within3 1.53(0.95-2.46) .08
After3 1.18(0.91-1.54) .21
aTheincidencerateratioreferstotheriskratioofthevitaminDgroupcomparedwiththeplacebogroup.Therateratio
within3monthsaftertreatmentissignificantlydifferentfromtherateratiooftheremaining9monthsaftertreatment
forfalls(P=.02)butnotforfracture(P=.36).
©2010AmericanMedicalAssociation.Allrightsreserved. (ReprintedwithCorrections)JAMA,May12,2010—Vol303,No.18 1819
Downloaded From: http://jama.jamanetwork.com/ by a Purdue University User on 05/18/2015
150 nmol/L or higher (FIGURE 4). By wereconsideredrelatedtostudymedi-
3 months, the after-dose median 25- cation.
hydroxycholecalciferol levels de-
COMMENT
creasedtoapproximately90nmol/Lin
thevitaminDgroup. Contrary to our hypothesis, partici-
pantsreceivingannualhigh-doseoral
AdverseEvents
cholecalciferolexperienced15%more
Asimilarnumberofparticipantsineach fallsand26%morefracturesthanthe
groupreportedatleast1adverseevent: placebogroup.Womennotonlyexpe-
19.7%inthevitaminDand17.8%in riencedexcessfracturesaftermorefre-
theplacebogroup.Themostcommon quentfallsbutalsoexperiencedmore
adverse events were injury including fracturesthatwerenotassociatedwith
fracture—15.2% (172 of 1131) of afall.Aposthocanalysisfoundthatthe
womentakingvitaminDvs12.1%(136 increasedlikelihoodoffallsinthevi-
of 1125) taking placebo (P=.03)— taminDgroupwasexacerbatedinthe
andcardiovascularevents—1.5%(171 3-month period immediately follow-
of1131)vs1.2%(13of1125),respec- ingtheannualdoseandasimilartem-
tively.Sevenwomen(0.6%)inthevi- poral trend was observed for frac-
taminDgroupvs10(0.9%)inthepla- tures. An increased risk (albeit, not
cebogroupwerediagnosedwithcancer. significant because of smaller num-
Serious adverse events (Interna- bers) of falls and fracture in the vita-
tionalConferenceonHarmonization/ minDgroupwasapparentforeachyear
WHO Good Clinical Practice defini- of the intervention. The results were
tionincludinghospitalizationordeath) similarafteradjustmentforbaselinecal-
didnotdiffersignificantly:244among cium intake; age was not included in
womentakingvitaminDvs207women themodelsbecauseitsinclusiondidnot
takingplacebo(P=.06).Eighty-seven affectthemodelestimates.
participantsdiedduringthestudy,40 Datafromthesubstudyindicatethat
taking vitamin D vs 47 taking pla- theparticipantshadintermediate25-hy-
cebo.Noneoftheseriousadverseevents droxycholecalciferollevelsatbaseline,
typical of community-dwelling older
Figure4.Serum25-HydroxycholecalciferolLevelsBeforeDose,andat1,3,and12Months womenoftheregion25andtypicalofolder
AfterDose womeninNorthernEuropeandNorth
America.33Theinterventioneffectively
175
increasedbackground25-hydroxycho-
lecalciferollevels.Predictably,thelev-
150
elsincreasedsubstantially1monthafter
dosingandthereafterdeclinedtoward
125
baselinebutremainingonaverage41%
higherthanlevelsintheplacebogroup
100 at12months.Thepatternisconsistent
Vitamin D
withserialmeasurementsdoneinolder
75 New Zealanders supplemented with
500000IUcholecalciferol.34
50 Only1otherstudyhasreportedanin-
Placebo creaseinfractureassociatedwithvita-
25 min D treatment.8 Participants (4354
men,5086women)75yearsorolderre-
0 ceivedanannualinjectionof300000IU
0 1 3 12 13 15 24
vitaminD asergocalciferolorplacebo.
Months Since Predose, 2006 2
No. of women
Vitamin D 50 54 51 53 52 54 54 Inmen,treatmenthadnoeffectonfrac-
Placebo 52 48 44 46 49 48 45 tures.Howeverwomentreatedwithvi-
taminDhadincreasedriskofnonver-
tebral(HR,1.21),hip/femur(HR,1.80),
and hip/femur/wrist/forearm fractures
L/lomn
,loreficlacelohcyxordyH
mureS
naideM
Figure3.Serum25-Hydroxycholecalciferol
LevelsatBaselineand12MonthsAfterDose
forEachYearoftheIntervention
150
Vitamin D
Placebo
100
50
0
Baseline 1 2 3 4 5
Year in Trial
No. of women
Vitamin D 74 57 36 54 39 16
Placebo 57 49 28 46 34 20
Thepointsrefertothemedianlevelof25-hydroxycholecalciferolatthetimeofbloodsamplingandtheerror
barsrepresenttheinterquartilerange.These7bloodsamplingtimepointstookplacein2006,2007,and2008,
andrefertothebiochemistrysubstudyparticipants.
L/lomn
,loreficlacelohcyxordyH
mureS
HIGH-DOSEVITAMINDANDFALLSANDFRACTURESINWOMEN
Serum25-hydroxycholecalciferollevelsinthevita-
minDgroupdifferfromthoseoftheplacebogroup
atall12-monthassessmentsafterdose(P(cid:3).05).The
mediansareshownasthehorizontalbarwithinthe
rectangleandtheinterquartilerangeastheendsof
therectangle.The5thand95thpercentilesareshown
aslines(whiskers),andtheclosedcirclesrepresentout-
liers.Theproportionofbiochemistrysubstudypar-
ticipantscategorizedinto25-hydroxycholecalciferolsta-
tusis(vitaminDgroup,n=74vsplacebogroup,n=57,
respectively)25nmol/Lorless:4%vs3.5%;26to
50nmol/L:41.9%vs57.9%;51to74nmol/L:44.5%
vs33.3%;75nmol/Lorhigher:9.5%vs5.3%.To
convert25-hydroxycholecalciferolfromnmol/Ltong/
mL,divideby2.496.
1820 JAMA,May12,2010—Vol303,No.18(ReprintedwithCorrections) ©2010AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a Purdue University User on 05/18/2015
HIGH-DOSEVITAMINDANDFALLSANDFRACTURESINWOMEN
(HR, 1.59). No effect on falls was ob- supplementation.14-18 Doses of 700 to erolof375to500nmol/L40becausethe
served; however, falls were a second- 800IUdailyreducedtheriskofnon- highest level at 1 month in the bio-
ary outcome and ascertainment was vertebralandhipfractureswithstron- chemistry substudy was 208 nmol/L.
basedon6-monthrecall.Baselineand gerevidenceofbenefitinreducinghip Pharmacokinetic studies in humans
changes in 25-hydroxycholecalciferol fractureriskwhentheanalysiswasre- givenasingle,largeoraldoseofcho-
andPTHlevelswereverysimilartoour strictedtoinstitutionalizedadults.18By lecalciferol indicate that 25-hydroxy-
results. Another common feature was contrast, a Cochrane review20 con- cholecalciferol levels peak at 7 to 21
that calcium supplements were not cludedthatvitaminDtherapyaloneap- days and thereafter decrease slowly
given.Whethercalciumsupplementa- pearedunlikelytobeeffectiveinpre- (half-life,60-90days),soitislikelythe
tionisbeneficialinvitaminDinterven- ventingfracture. peaklevelswereonlymarginallyhigher
tion studies is uncertain. Studies that Evidence of risk reduction of falls than the 1-month levels.24,41 Further-
haveshownreductionsinfracturewith withvitaminDsupplementationwith more,theincrementalincreasein25-
vitamin D therapy have variously and without calcium is also inconsis- hydroxycholecalciferol is likely to be
used4,9,10ornotused3,7acalciumsupple- tent.Overallthereappearstobean11% lowerinthosealreadyrepletepriorto
ment. The RECORD (Randomised to 19% reduction in fall risk with supplementation.34
EvaluationofCalciumorVitaminD)2 supplementation and a possible dose This is the first study to demon-
studyshowednobenefitofaddingcal- thresholdof700to1000IUdaily.18,23 strateincreasedriskoffallsassociated
ciumtovitaminD,usingafactorialran- Nofallriskreductionwasobservedfor withanyvitaminDinterventionandthe
domizedstudydesign. dosesoflessthan700IUorachieved second study to demonstrate an in-
ThestudyofChapuyetal4treatedfe- serum 25-hydroxycholecalciferol lev- creasedfractureriskassociatedwithan-
malenursinghomeresidents(mean25- elsoflessthan60nmol/L,consistent nualhigh-dosevitaminDtherapyinel-
hydroxycholecalciferol level, 36 with an earlier review of trials using derly women. Our study used the
nmol/L)with800IUoforalcholecal- varying doses of vitamin D that con- largesttotalannualdoseofvitaminD
ciferol plus 1.2 g of calcium or pla- cludedthattherewasinsufficientevi- (500000IU)reportedinanylargeran-
cebo taken daily. Hip and nonverte- dencethatcholecalciferoltreatmentre- domized controlled trial, raising the
bralfracturesweresignificantlyreduced ducedfalls.36Currently600IU(15µg) possibilitythattheadverseoutcomeis
byabout25%.Likewise,incommunity- perdayisrecommendedforadults70 dose-related.Theopposingoutcomes
dwelling men and women random- yearsorolderintheUnitedStatesand of2studies3,8thatusedthesametotal
izedtoreceive100000IUoforalcho- Canada37,38withanupperlimitof2000 annualdose(300000IUintramuscu-
lecalciferolin4monthlydoses,Trivedi IUperday(~700000IUperyear).Cho- larly)suggestthatthedosingregimen
et al3 showed reductions in any frac- lecalciferol1000IUislistedontheAus- (ie,4monthlyvsannually)ratherthan
tureandfractureatthehip,wrist,fore- tralianRegisteroftherapeuticgoods.Al- thetotaldosemightdeterminetheout-
arm, or spine. Other studies report thoughourresultscannotnecessarily come. This line of reasoning is sup-
eitherreductions7,9,10ornoeffect1,2,6,11,35 beappliedtohigh-dosevitaminDad- portedbythetemporalriskpatternthat
in fracture rates in the active groups. ministered in divided doses over the weobservedandthefactthatharmhas
TheWomen’sHealthInitiativestudy1 year,theysuggestthatfurtherstudyto not been reported in the numerous
showednoeffectofdailycalciumplus assesssafetyisneeded. studies that have used more frequent
400IUofcholecalciferolonfractures. The major strength of our study is dosing.Thus,itisreasonabletospecu-
TheRECORDstudy2showednoeffect thatitwasalargerandomized,double- latethathighserumlevelsofvitamin
insecondarypreventionoffracturesor blind, placebo-controlled trial. Falls D or metabolites resulting from the
fallsinelderlyparticipantstreateddaily and fracture ascertainment were ro- large annual dose, subsequent de-
with 800 IU of cholecalciferol alone, bust,29,39 although nonclinical verte- crease in the levels, or both might be
cholecalciferol plus calcium, or cal- bralfractureswouldhavebeenmissed. causal.Furthermore,becausethelev-
cium alone, although only 54% were Thepragmaticdesignofthestudypro- elsof25-hydroxycholecalciferoldem-
still taking study medication at 24 videdhighpotentialfortranslationinto onstratedinthisstudycouldoccurwith
months.Otherstudiesusingintermit- publichealthpolicyandclinicalprac- other recommended dosing regi-
tentoralvitaminDinolderpeopleliv- tice.Themainweaknessesofthestudy mens,42,43theoutcomeofthisstudysug-
inginresidentialcaredidnotshowany are also related to its pragmatic de- gests that safety of high-dose vitamin
reductioninfractures.11,13 sign—theparticipantswerenotevalu- D supplementation warrants further
Meta-analysessuggestthatthereisa ated at the study center so that base- study.
threshold level for vitamin D supple- lineclinicalinformationmayhavebeen
AuthorContributions:DrSandershadfullaccessto
mentation of more than 400 IU daily missed.Biochemicalassessmentofall
allofthedatainthestudyandtakesresponsibilityfor
forfractureriskreductionandthatre- participantswasnotpossible.Wedonot theintegrityofthedataandtheaccuracyofthedata
ductionsinhipandnonvertebralfrac- expect that any participants reached analysis.
Studyconceptanddesign:Sanders,Kotowicz,Young,
tures are independent of calcium toxiclevelsof25-hydroxycholecalcif- Nicholson.
©2010AmericanMedicalAssociation.Allrightsreserved. (ReprintedwithCorrections)JAMA,May12,2010—Vol303,No.18 1821
Downloaded From: http://jama.jamanetwork.com/ by a Purdue University User on 05/18/2015
HIGH-DOSEVITAMINDANDFALLSANDFRACTURESINWOMEN
Acquisitionofdata:Sanders,Stuart. turesinelderlycommunitydwellingresidents:aprag- 26. SandersK,StuartA,MerrimanE,etal.Trialsand
Analysisandinterpretationofdata:Sanders,Stuart, maticpopulation-based3-yearinterventionstudy. tribulationsofrecruiting2,000olderwomenontoa
Williamson,Simpson,Kotowicz,Nicholson. JBoneMinerRes.2004;19(3):370-378. clinicaltrialinvestigatingfallsandfractures:VitalD
Draftingofthemanuscript:Sanders,Stuart. 10. Dawson-HughesB,HarrisS,KrallE,DallalG.Effect study.BMCMedResMethodol.2009;9(1):78.doi:
Criticalrevisionofthemanuscriptforimportantin- ofcalciumandvitaminDsupplementationonbone 10.1186/1471-2288-1189-1178.
tellectualcontent:Sanders,Williamson,Simpson, densityinmenandwomen65yearsofageorolder. 27. CummingsS,NevittM,BrownerW,etal;Study
Kotowicz,Nicholson. NEnglJMed.1997;337(10):670-676. ofOsteoporoticFracturesResearchGroup.Riskfac-
Statisticalanalysis:Sanders,Stuart,Williamson,Simpson. 11. LyonsR,JohansenA,BrophyS,etal.Preventing torsforhipfracturesinwhitewomen.NEnglJMed.
Obtained funding: Sanders, Kotowicz, Young, fracturesamongolderpeoplelivingininstitutionalcare: 1995;332(12):767-773.
Nicholson. apragmaticrandomiseddoubleblindplacebocon- 28. RubensteinL,RobbinsA,JosephsonK,Schulman
Administrative,technical,ormaterialsupport:Stuart, trolledtrialofvitaminDsupplementation.Osteopo- B,OsterweilD.Thevalueofassessingfallsinanel-
Nicholson. rosInt.2007;18(6):811-818. derlypopulation:arandomisedclinicaltrial.AnnIn-
Studysupervision:Sanders,Nicholson. 12. PrinceR,AustinN,DevineA,DickI,BruceD,Zhu ternMed.1990;113(4):308-316.
FinancialDisclosures:Nonereported. K.Effectsofergocalciferoladdedtocalciumonthe 29. CummingR.Injuryepidemiologyandolderpeople:
Funding/Support:Thestudywassupportedbyproject riskoffallsinelderlyhigh-riskwomen.ArchInternMed. countingandanalysingdataonfalls.Australasian
grantNo.251682fromtheNationalHealthandMedi- 2008;168(1):103-108. Epidemiologist.2000;7(1):10-12.
calResearchCouncilandbytheAustralianGovern- 13. LawMR,WaldNJ,MeadeTW.Strategiesforpre- 30. AngusRM,SambrookPN,PocockNA,Eisman
mentDepartmentofHealthandAgeing. ventionofosteoporosisandhipfracture.BMJ.1991; JA.Asimplemethodforassessingcalciumintakein
RoleoftheSponsor:Thefundingorganizationswere 303(6800):453-459. Caucasianwomen.JAmDietAssoc.1989;89(2):
independentofthedesignandconductofthestudy; 14. Bischoff-FerrariH,WillettW,WongJ,Giovannucci 209-214.
collection,management,analysis,andinterpretation E,DietrichT,Dawson-HughesB.Fracturepreven- 31. SandersK,SeemanE,UgoniA,etal.Age-and
ofthedata;andpreparation,review,orapprovalof tion with vitamin D supplementation: a meta- gender-specificrateoffracturesinAustralia:apopu-
themanuscript. analysisofrandomizedcontrolledtrials.JAMA.2005; lationbasedstudy.OsteoporosInt.1999;10(3):
AdditionalContributions:WethankBarwonHealth 293(18):2257-2264. 240-247.
employeesPaulMuir,BPharm,BA,FSHP(clinicaltrials 15. Bischoff-FerrariH,WillettW,WongJ,etal.Pre- 32. PascoJ,HenryM,KotowiczM,etal.Seasonalpe-
pharmacist),ElizabethMerriman,BSc(studycoordi- ventionofnonvertebralfractureswithoralvitaminD riodicityofserumvitaminDandparathyroidhor-
nator2005to2006),andCathyVerecondi(admin- anddosedependency:ameta-analysisofrandom- mone,boneresorption,andfractures:theGeelongOs-
istrativeofficer)fortheirhelpaspartoftheirregular izedcontrolledtrials.ArchInternMed.2009;169 teoporosisStudy.JBoneMinerRes.2004;19(5):
dutiesandgratefullyacknowledgethe2317women (6):551-561. 752-758.
whoparticipatedinthestudy. 16. TangB,EslickG,NowsonC,SmithC,Bensoussan 33. MithalA,WahlD,BonjourJ,etal;IOFCommit-
A.Useofcalciumorcalciumincombinationwithvi- teeofScientificAdvisors(CSA)NutritionWorking
taminDsupplementationtopreventfracturesandbone Group.GlobalvitaminDstatusanddeterminantsof
REFERENCES lossinpeopleaged50yearsandolder:ameta-analysis. hypovitaminosisD.OsteoporosInt.2009;20(11):
Lancet.2007;370(9588):657-666. 1807-1820.
1. JacksonR,LaCroixA,GassM,etal;Women’sHealth 17. ReidI,BollandM,GreyA.Effectofcalciumsupple- 34. BaconC,GambleG,HorneA,ScottM,ReidI.
InitiativeInvestigators.CalciumplusvitaminDsupple- mentationonhipfractures.OsteoporosInt.2008; High-dosevitaminD supplementationintheelderly.
3
mentationandtheriskoffractures.NEnglJMed.2006; 19(8):1119-1123. OsteoporosInt.2009;20(8):1407-1415.
354(7):669-683. 18. CranneyA,WeilerH,O’DonnellS,PuilL.Sum- 35. LawM,WithersH,MorrisJ,AndersonF.Vita-
2. GrantA,AndersonF,AvenellA,etal.Oralvita- maryofevidence-basedreviewonvitaminDefficacy minDsupplementationandthepreventionoffrac-
minD3andcalciumforsecondarypreventionoflow- andsafetyinrelationtobonehealth.AmJClinNutr. turesandfalls:resultsofarandomisedtrialinelderly
traumafracturesinelderlypeople(RandomisedEvalu- 2008;88(2):513S-519S. peopleinresidentialaccommodation.AgeAgeing.
ationofCalciumorVitaminD,RECORD).Lancet.2005; 19. JacksonC,GaugrisS,SenS,HoskingD.Theeffect 2006;35(5):482-486.
365(9471):1621-1628. ofcholecalciferol(vitaminD)ontheriskoffalland 36. LathamN,AndersonC,ReidI.Effectsofvitamin
3
3. TrivediD,DollR,KhawK.Effectoffourmonthly fracture:ameta-analysis.QJM.2007;100(4):185- Dsupplementationonstrength,physicalperfor-
oralvitaminDsupplementationonfracturesandmor- 192. mance, and falls in older persons: a systematic
talityinmenandwomenlivinginthecommunity:ran- 20. AvenellA,GillespieW,GillespieL,O’ConnellD. review. J Am Geriatr Soc. 2003;51(9):1219-
domiseddoubleblindcontrolledtrial.BMJ.2003; VitaminDandvitaminDanaloguesforpreventing 1226.
326(7387):469-475. fracturesassociatedwithinvolutionalandpost- 37. HealthCanada.VitaminD:recommendationsand
4. ChapuyMC,ArlotME,DelmasPD,MeunierP.Effect menopausalosteoporosis.CochraneDatabaseSystRev. reviewstatus.http://www.hc-sc.gc.ca/fn-an/nutrition
ofcalciumandcholecalciferoltreatmentforthreeyears 2009;2(2):CD000227. /vitamin/vita-d-eng.php.UpdatedJuly23,2009.Ac-
onhipfracturesinelderlywomen.BMJ.1994; 21. DIPARTgroup.Patientlevelpooledanalysisof cessedApril2010.
308(6936):1081-1082. 68500patientsfromsevenmajorvitaminDfracture 38. OfficeofDietarySupplements,NationalInsti-
5. ChapuyMC,ArlotME,DuboeufF,etal.Vitamin trialsinUSandEurope.BMJ.2010;340:b5463.doi: tutesofHealth.DietarySupplementFactSheet:Vi-
D andcalciumtopreventhipfracturesinelderly 10.1136/bmj.b5463. tamin D Health Professional Fact Sheet. http:
3
women.NEnglJMed.1992;327(23):1637-1642. 22. IzaksG.FracturepreventionwithvitaminDsupple- //dietary-supplements.info.nih.gov/factsheets
6. PorthouseJ,CockayneS,KingC,etal.Ran- mentation:consideringtheinconsistentresults.BMC /vitamind.asp#h2.AccessedApril2010.
domisedcontrolledtrialofcalciumandsupplemen- MusculoskeletDisord.2007;8:26. 39. LordS,SherringtonC,MenzH.Fallsinolder
tationwithcholecalciferol(vitaminD)forpreven- 23. Bischoff-FerrariH,Dawson-HughesB,Staehelin people:methodologicalconsiderations.Australasian
3
tionoffracturesinprimarycare.BMJ.2005;330 H,etal.Fallspreventionwithsupplementalandac- Epidemiologist.2000;7.1:13-17.
(7498):1003. tiveformsofvitaminD:ameta-analysisofran- 40. JonesG.PharmokineticsofvitaminDtoxicity.Am
7. HeikinheimoR,InkovaaraJA,HarjuEJ,etal.An- domisedtrials.BMJ.2009;339:b3692.doi:10.1136 JClinNutr.2008;88(2)(suppl):582s-586s.
nualinjectionofvitaminDandfracturesofagedbones. /bmj.b3692. 41. IlahiM,ArmasL,HeaneyR.Pharmokineticsofa
CalcifTissueInt.1992;51(2):105-110. 24. WuF,StaykovaT,HorneA,etal.Efficacyofan single,largedoseofcholecalciferol.AmJClinNutr.
8. SmithH,AndersonF,RaphaelH,MaslinP,Crozier oral,10-daycourseofhighdosecalciferolincorrect- 2008;87(3):688-691.
S,CooperC.Effectofannualintramuscularvitamin ingvitaminDdeficiency.NZMedJ.2003;116 42. PietrasS,ObayanB,CaiM,HolickM.Vitamin
Donfractureriskinelderlymenandwomen:apopu- (1179):U536. D treatmentforvitaminDdeficiencyandinsuffi-
2
lation-based,randomized,double-blind,placebo- 25. PascoJ,HenryM,NicholsonG,SandersK, ciencyforupto6years.ArchInternMed.2009;
controlledtrial.Rheumatology(Oxford).2007; KotowiczM.VitaminDstatusofwomenintheGee- 169(19):1806-1808.
46(12):1852-1857. longOsteoporosisStudy:associationwithdietandca- 43. HeaneyR.VitaminD:criteriaforsafetyand
9. LarsenE,MosekildeL,FoldspangA.VitaminDand sualexposuretosunlight.MedJAust.2001;175 efficacy. Nutr Rev. 2008;66(10)(suppl 2):s178-
calciumsupplementationpreventsosteoporoticfrac- (8):401-405. s181.
1822 JAMA,May12,2010—Vol303,No.18(ReprintedwithCorrections) ©2010AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a Purdue University User on 05/18/2015
